Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042
Authors:
- Nathalie AccartNANathalie Accart
- Mirjana Urosevic-MaiwaldMUMirjana Urosevic-Maiwald
- Reinhard DummerReinhard Dummer
- Vincent BatailleVBVincent Bataille
- Nadine KehrerNKNadine Kehrer
- Cristina NiculescuCNCristina Niculescu
- Jean-Marc LimacherJLJean-Marc Limacher
- Marie-Pierre ChenardMCMarie-Pierre Chenard
- Jean-Yves BonnefoyJBJean-Yves Bonnefoy
- Ronald RookeRRRonald Rooke
Open Access
- 25 September 2013
- journal article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 11 (1) , 226
Abstract
Background: Primary cutaneous lymphomas (CLs), characterized by an accumulation of clonal T or B lymphocytes preferentially localized in the skin, have been successfully treated with interferons (IFNs) which counterbalance the Th2-immunosuppressive state associated with this pathology. In a phase I/II clinical trial, we correlated the local immune infiltrate and the anti-tumor effects of repeated intralesional administrations of an adenovirus vector expressing human interferon-gamma (IFN-g) termed TG1042, in patients with advanced primary cutaneous T-cell lymphomas (CTCL) or multilesional cutaneous B-cell lymphomas (CBCL). Methods: For each patient, variation in time of specific lymphocyte populations, defined by immunohistochemical stainings, was assessed in biopsies of injected lesions. For each patient, the change in local immune response was associated with the patient’s objective response at the end of the study. Results: Immunohistochemical analyses of biopsies indicate that infiltration of CD8+ T lymphocytes and of TIA-1+ cytotoxic T-cells in lesions injected with TG1042 correlates with clinical benefit. Conclusions: These data suggest for the first time that a CD8+ cytotoxic infiltrate, induced by local expression of IFN-g correlates with a clinical response. Trial registration: The phase I step (TG1042.01) does not have a registration number. The phase II step (TG1042.06) registration number was NCT00394693.Keywords
This publication has 24 references indexed in Scilit:
- The Th1 life cycle: molecular control of IFN-γ to IL-10 switchingTrends in Immunology, 2011
- Phase II Clinical Trial of Intratumoral Application of TG1042 (Adenovirus-interferon-γ) in Patients With Advanced Cutaneous T-cell Lymphomas and Multilesional Cutaneous B-cell LymphomasMolecular Therapy, 2010
- Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Blood, 2007
- WHO-EORTC classification for cutaneous lymphomasBlood, 2005
- Adenovirus-mediated intralesional interferon-γ gene transfer induces tumor regressions in cutaneous lymphomasBlood, 2004
- Interferon-γ: an overview of signals, mechanisms and functionsJournal of Leukocyte Biology, 2003
- The roles of IFNγ in protection against tumor development and cancer immunoeditingCytokine & Growth Factor Reviews, 2002
- Signaling and Transcription in T Helper DevelopmentAnnual Review of Immunology, 2000
- Aberrant Cytokine Production By Sezary Syndrome Patients: Cytokine Secretion Pattern Resembles Murine Th2 CellsJournal of Investigative Dermatology, 1992
- Immunophenotypic and genotypic characterization of lymphomatoid papulosisJournal of the American Academy of Dermatology, 1992